EASTONBIOPHARMACEUTICALS(SH:688513) Shang Hai Zheng Quan Bao·2025-10-13 19:17Core Viewpoint - Chengdu Yuandong Biopharmaceutical Co., Ltd. has recognized Mr. Zhao Liwen as a core technical personnel to enhance the company's innovation capabilities and accelerate the implementation of its innovation transformation strategy [1][3]. Summary by Sections New Core Technical Personnel - Mr. Zhao Liwen, born in November 1973, holds a doctoral degree from the Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, and has over 15 years of experience in pharmaceutical R&D management [1][2]. - He has previously held significant positions at Nanjing Shenghe Pharmaceutical Co., Ltd. and is currently the CEO of Shanghai Chaoyang Pharmaceutical Co., Ltd. [1][2]. Impact on the Company - The decision to recognize Mr. Zhao as a core technical personnel is based on his professional background, work experience, research achievements, and potential contributions to the company's R&D projects and business development [3]. - The company plans to maintain a high proportion of R&D investment and improve its technical innovation mechanisms, while also enhancing the development of its R&D team by attracting more talented researchers and managers [3].